In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tighter FDA Review Squeezing Device VCs

Executive Summary

For over three decades, medical device investors have accepted the Food and Drug Administration's crucial role as traffic cop for their start-ups. Yes, the agency could be tough, but a green light opened a lucrative road for device companies. But venture capitalists are increasingly worried that tighter controls on regulation could endanger innovation.
Advertisement

Related Content

Following the Money in Medical Devices
Has Orthovita's Fight Finally Ended?
Asthmatx Positive Panel Outcome Good Sign for Pulmonology Companies
Changing Minds at the FDA
Changing Minds at the FDA
Emphysema Devices Search for Breathing Room
Emphysema: Elusive Target for Device Companies
Asthmatx Breathes Easier
Novasys: Using Clinical Trials to Drive Adoption for Incontinence
Emphasys Medical Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel